Fact-checked by Grok 2 weeks ago

PCSK9

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease encoded by the PCSK9 gene on human chromosome 1p32.3, which regulates low-density lipoprotein (LDL) cholesterol homeostasis by binding to LDL receptors (LDLR) on the surface of hepatocytes and promoting their internalization and lysosomal degradation.^[1]^[2]^[3]
Originally identified in 2003 through genetic studies linking missense mutations to autosomal dominant hypercholesterolemia, PCSK9's gain-of-function variants reduce LDLR recycling, elevating circulating LDL cholesterol and increasing atherosclerotic cardiovascular disease risk, whereas loss-of-function mutations enhance LDL clearance and correlate with reduced coronary heart disease incidence.^[4]^[5]^[6]
The protein's therapeutic targeting via monoclonal antibodies such as evolocumab and alirocumab inhibits this degradative pathway, achieving LDL cholesterol reductions of 50-60% in clinical trials and demonstrating significant decreases in major adverse cardiovascular events among statin-intolerant or high-risk patients refractory to conventional lipid-lowering therapies.^[7]^[8]^[9]
Beyond lipid metabolism, emerging evidence suggests PCSK9 influences glucose homeostasis, inflammation, and vascular function, though its primary clinical significance remains in cardiovascular risk management.^[10]^[11]

History and Discovery

Initial Identification and Genetic Studies

The PCSK9 gene, encoding proprotein convertase subtilisin/kexin type 9, was first identified in February 2003 by Nabil G. Seidah and colleagues through differential display PCR screening of mRNAs upregulated during apoptosis in human cerebellar granule neurons. Initially named neural apoptosis-regulated convertase-1 (NARC-1), the protein was characterized as a secreted enzyme belonging to the proprotein convertase family, featuring a signal peptide, prodomain, subtilisin-like catalytic domain, and cysteine-histidine-rich domain, with predominant expression in neuroepithelial tissues, liver, and intestines. In June 2003, Marianne Abifadel and her team reported genetic linkage studies in families exhibiting autosomal dominant hypercholesterolemia (ADH) unresponsive to LDLR or APOB mutations.^[4] They localized a novel ADH locus, HCHOLA3, to chromosome 1p32 via parametric linkage analysis, achieving a maximum LOD score of 3.89. Sequencing revealed two heterozygous missense mutations in PCSK9—S127R in a French family and D374Y in a Canadian pedigree—both resulting in gain-of-function effects that elevate plasma LDL cholesterol by approximately 30-40% through enhanced degradation of hepatic LDL receptors.^[12] These findings established PCSK9 as a key regulator of cholesterol metabolism and the third major gene implicated in monogenic hypercholesterolemia.^[4] Subsequent genetic studies confirmed the 1p32 locus and expanded the spectrum of PCSK9 variants, with loss-of-function mutations later identified as protective against coronary heart disease by reducing LDL levels. The gene spans approximately 25 kb, comprising 12 exons, and its discovery bridged molecular enzymology with clinical genetics, paving the way for therapeutic targeting.^[1]

Key Research Milestones and Timeline

In 2003, Nabil G. Seidah and colleagues cloned the PCSK9 gene, identifying it as the ninth member of the proprotein convertase family (initially termed NARC-1), an autocatalytically cleaved but enzymatically inactive protease with predominant expression in liver hepatocytes and small intestine cerebroid cells.^[13] Later that year, Marianne Abifadel et al. reported gain-of-function mutations (S127R and F216L) in PCSK9 among three French families with autosomal dominant hypercholesterolemia, demonstrating 1.5- to 3.5-fold elevations in LDL cholesterol and establishing PCSK9 as a causal factor in rare familial hypercholesterolemia cases.^[13] By 2004, additional gain-of-function variants such as D374Y were identified in Norwegian and Utah cohorts, further linking PCSK9 hyperactivity to severe LDL elevation.^[13] Mechanistic insights emerged in 2004–2005, with studies by Maxwell, Breslow, and others revealing that secreted PCSK9 binds epidermal growth factor-like repeats on the LDL receptor (LDLR), preventing its endosomal dissociation and recycling while directing it to lysosomal degradation in hepatocytes, thereby reducing surface LDLR density and plasma LDL clearance.^[11] In 2005, Jonathan C. Cohen et al. discovered loss-of-function nonsense mutations (Y142X and C679X) in PCSK9 among African Americans, associated with approximately 40% lower LDL-C levels and a 88% reduced risk of coronary heart disease, providing genetic evidence for PCSK9's causal role in atherogenic dyslipidemia without enzymatic activity requirement.^[11] Concurrently, Pcsk9 knockout mice exhibited expanded hepatic LDLR pools, plasma cholesterol reductions of up to 44%, and heightened statin responsiveness, confirming the pathway's conservation and therapeutic potential.^[11] From 2006 onward, population studies expanded on loss-of-function variants (e.g., R46L, C679X), showing lifelong LDL-C lowering and cardiovascular protection in diverse cohorts, while animal and cellular models delineated PCSK9-LDLR trafficking dynamics involving clathrin-mediated endocytosis.^[8] Preclinical antagonism via antisense oligonucleotides and monoclonal antibodies in rodents and nonhuman primates achieved 50–80% LDLR upregulation and LDL-C reductions by 2008–2010, paving the way for human translation.^[14] The first phase I trials of anti-PCSK9 monoclonal antibodies (e.g., REGN727/SAR236553, AMG 145) commenced in 2011–2012, demonstrating dose-dependent LDL-C drops of 40–70% in healthy volunteers and hypercholesterolemic patients, with favorable safety.^[15] Phase III efficacy trials (e.g., MENDEL-2, GAUSS-2) from 2013–2014 confirmed additive LDL-C lowering atop maximally tolerated statins, leading to FDA approvals in 2015: alirocumab (Praluent) on July 24 for heterozygous familial hypercholesterolemia and statin-intolerant high-risk patients, followed by evolocumab (Repatha).^[16] ^[17] Outcomes trials solidified clinical utility: the FOURIER trial (2017) reported evolocumab reduced major adverse cardiovascular events by 20% in statin-treated patients with LDL-C >70 mg/dL, while ODYSSEY Outcomes (2018) showed alirocumab's 15% event reduction post-acute coronary syndrome.^[18] Inclisiran, an siRNA targeting hepatic PCSK9 synthesis, gained FDA approval in 2021, offering biannual dosing with 50% LDL-C reductions in phase III ORION trials.^[11] Ongoing research explores oral small-molecule inhibitors and broader applications in non-cardiovascular conditions like inflammation and viral entry.^[11]

Genetics and Molecular Structure

Gene Organization and Variants

The PCSK9 gene is situated on the short arm of human chromosome 1 at cytogenetic band 1p32.3, encompassing a genomic region of approximately 22-25 kilobases from nucleotide positions 55,039,445 to 55,064,852 on the reference genome (GRCh38).^[19]^[1] This location was mapped through genomic sequence analysis, confirming its role in lipid metabolism pathways.^[6] The gene structure includes 12 exons separated by 11 introns, as determined by early sequencing efforts that revealed the full exon-intron organization.^[6]^[20] These exons encode a 692-amino-acid preproprotein, which undergoes processing to form the mature PCSK9 enzyme consisting of a prodomain and catalytic domain.^[20] Alternative splicing produces multiple transcripts, though the canonical isoform predominates in hepatic expression.^[19] Genetic variants in PCSK9 span loss-of-function (LOF) and gain-of-function (GOF) mutations, alongside common polymorphisms influencing lipid levels. LOF variants, often nonsense, frameshift, or missense changes reducing PCSK9 secretion or activity, correlate with lifelong reductions in low-density lipoprotein cholesterol (LDL-C) by 15-40% and lower coronary heart disease risk, as observed in population studies.^[21] Notable examples include the Y142X and C679X nonsense mutations.^[6] In contrast, over 50 GOF mutations, primarily missense alterations in the catalytic or C-terminal domains, enhance PCSK9-mediated LDL receptor degradation, causing autosomal dominant hypercholesterolemia with elevated LDL-C levels.^[2] These include D374Y and D374H, which increase PCSK9 affinity for the LDL receptor.^[22] Common polymorphisms such as E670G (rs505151) associate with modestly higher LDL-C and atherosclerotic risk, while intronic variants like rs2483205 and rs562556 modulate PCSK9 expression and cardiovascular outcomes in cohort analyses.^[23]^[24] Rare variants require functional validation, as population databases like gnomAD reveal allele frequencies informing pathogenicity.^[25]

Protein Structure and Domains

PCSK9 is synthesized as a 692-amino-acid precursor protein consisting of a signal peptide (residues 1-30), a prodomain (residues 31-152), a catalytic domain (residues 153-421), and a C-terminal cysteine-histidine-rich domain (CHRD, residues 422-692).^[11] ^[26] Following translocation into the endoplasmic reticulum, the signal peptide is cleaved, and the prodomain undergoes autocatalytic cleavage at the VFAQ↓SIP site between residues 152 and 153, yet remains tightly bound to the catalytic domain in a non-covalent complex.^[27] This interaction occludes the catalytic site, rendering the protease inactive toward external substrates while stabilizing the protein for secretion.^[28] The catalytic domain adopts a subtilisin-like serine protease fold, characterized by a catalytic triad (Asp177, His236, Ser386) typical of proprotein convertases, though its activity is autoinhibited by the prodomain.^[29] Crystal structures, such as PDB entry 2P4E resolved at 1.9 Å resolution, reveal the prodomain covering the active site cleft, with key hydrogen bonds and hydrophobic interactions maintaining the inhibited conformation.^[30] Mutations disrupting this prodomain-catalytic interface, such as those altering residues in the P1' position post-cleavage, impair folding, autocleavage, and subsequent LDL receptor binding.^[31] The C-terminal CHRD comprises three tandem modules (M1: residues 422-530, M2: 531-620, M3: 621-692), each featuring a six-stranded β-sheet core stabilized by disulfide bonds and histidine residues, exhibiting quasi-threefold symmetry.^[32] This domain is essential for PCSK9 secretion and interaction with the LDL receptor's epidermal growth factor precursor homology domain A (EGF-A), with the M2 module primarily mediating binding.^[11] Structures of PCSK9-LDLR complexes, like PDB 3P5C, demonstrate that the CHRD remains solvent-exposed, facilitating cofactor interactions, while the receptor adopts an extended conformation upon binding.^[33] Overall, the modular architecture underscores PCSK9's role as a chaperone-like regulator rather than an active protease in post-secretory function.^[34]

Physiological Roles

Regulation of LDL Receptor and Cholesterol Homeostasis

Proprotein convertase subtilisin/kexin type 9 (PCSK9) primarily regulates low-density lipoprotein receptor (LDLR) expression on hepatocytes by directing the receptor toward lysosomal degradation, thereby controlling plasma low-density lipoprotein cholesterol (LDL-C) levels. Secreted PCSK9 binds to the epidermal growth factor precursor homology domain A (EGF-A) of cell-surface LDLR, facilitating co-internalization through clathrin-mediated endocytosis.^[35] In the acidic environment of the endosome, this binding affinity increases, inhibiting LDLR's dissociation from PCSK9 and preventing its recycling to the plasma membrane; instead, the complex traffics to lysosomes where LDLR undergoes proteasomal and lysosomal degradation.^[35] ^[36] This post-translational mechanism reduces hepatic LDLR density by up to 80% in experimental models, directly impairing the receptor's ability to bind and internalize circulating LDL particles via apolipoprotein B100 (apoB100).^[37] Consequently, LDL-C clearance from plasma diminishes, elevating circulating LDL-C concentrations and contributing to cholesterol homeostasis dysregulation in hypercholesterolemic states.^[38] Circulating PCSK9 can also interact with apoB100 on LDL particles, which modulates its availability for LDLR binding and fine-tunes degradation efficiency.^[35] In cholesterol homeostasis, PCSK9 integrates with sterol regulatory element-binding protein 2 (SREBP-2) pathways: low intracellular cholesterol activates SREBP-2, inducing both LDLR and PCSK9 transcription to balance uptake and limit excessive accumulation.^[39] Gain-of-function PCSK9 mutations enhance LDLR degradation, reducing receptor levels and promoting hypercholesterolemia, as observed in familial forms where plasma LDL-C rises by 2-3 fold.^[36] Conversely, loss-of-function variants decrease PCSK9 activity, increasing LDLR recycling and lowering LDL-C by 15-40%, underscoring PCSK9's pivotal role in maintaining hepatic cholesterol equilibrium.^[37] This regulation extends beyond the liver minimally, as extra-hepatic LDLR effects are less pronounced due to lower PCSK9 expression elsewhere.^[40]

Extra-Hepatic Functions and Broader Metabolic Impacts

PCSK9 exhibits expression in multiple extra-hepatic tissues, including the pancreas, small intestine, kidney, adipose tissue, and central nervous system, where it modulates receptor degradation and cellular processes beyond primary hepatic LDL receptor (LDLR) regulation.^[41] These functions often involve LDLR family members like VLDLR and ApoER2, as well as LDLR-independent pathways such as CD36 degradation, influencing lipid uptake and storage.^[11] Experimental models demonstrate that PCSK9 knockout in mice alters lipid accumulation in non-hepatic sites, such as increased hepatic but also peripheral triglyceride storage under high-fat diets, highlighting pleiotropic metabolic roles.^[11] In the pancreas, PCSK9 is predominantly expressed in delta cells and has been linked to glucose metabolism, with in vitro studies showing it impairs insulin secretion from beta cells via enhanced LDLR degradation and potential disruption of cholesterol-dependent signaling.^[42] However, rodent models yield conflicting results: PCSK9 deficiency sometimes protects against hyperglycemia, while other data indicate worsened glucose tolerance due to altered incretin signaling.^[43] Human clinical trials of PCSK9 inhibitors, such as the FOURIER study (2017) involving evolocumab over 2.2 years, report no increased incidence of new-onset diabetes, suggesting minimal adverse metabolic impact in vivo despite theoretical concerns.^[11] PCSK9 influences intestinal cholesterol absorption by locally degrading LDLR on enterocytes, reducing uptake of dietary lipids; inhibition in mouse models elevates intestinal LDLR levels and modestly increases cholesterol excretion.^[14] In the kidney, circulating PCSK9 promotes podocyte LDLR degradation, contributing to lipid accumulation, proteinuria, and fibrosis in models of nephrotic syndrome; observational data from 2018 associate elevated serum PCSK9 with declining glomerular filtration rates in chronic kidney disease patients.^[43] Adipose tissue expression of PCSK9 regulates CD36-mediated free fatty acid uptake, with deficiency leading to enhanced triglyceride storage and potential links to insulin resistance in high-fat-fed mice.^[11] Broader metabolic effects extend to neuro-metabolic regulation in the brain, where PCSK9 degrades VLDLR and ApoER2, impacting neuronal cholesterol supply, differentiation, and synaptic function; zebrafish and mouse studies from 2006-2020 show PCSK9 promotes neurogenesis but exacerbates post-stroke inflammation via NF-κB activation.^[44] These extra-hepatic actions underscore PCSK9's role in systemic lipid partitioning and energy homeostasis, with therapeutic inhibition appearing neutral or beneficial for renal and neurological outcomes in preclinical data, though long-term human metabolic effects require further scrutiny.^[43]

Clinical Associations

Genetic Mutations and Familial Hypercholesterolemia

Gain-of-function (GOF) mutations in the PCSK9 gene cause a rare autosomal dominant form of familial hypercholesterolemia (FH), designated as autosomal dominant hypercholesterolemia type 3 (ADH3). These mutations enhance the protein's ability to bind and promote lysosomal degradation of low-density lipoprotein receptors (LDLR) on hepatocyte surfaces, reducing LDL cholesterol clearance and elevating plasma LDL-C levels from birth.^[4] Unlike loss-of-function variants that protect against hypercholesterolemia, GOF alleles increase PCSK9 affinity for LDLR or impair its own degradation, leading to fewer functional receptors and severe dyslipidemia.^[45] This mechanism was first elucidated following the identification of PCSK9 as a key regulator of cholesterol homeostasis in 2003.^[12] The initial GOF mutations, S127R and F216L, were reported in 2003 in French and Canadian families with ADH lacking LDLR or APOB defects, mapping to chromosome 1p32.^[4] Subsequent studies identified over 30 such variants, including highly penetrant ones like D374Y and D374H in the catalytic domain, which confer the most severe phenotype with untreated LDL-C exceeding 13 mmol/L (500 mg/dL) and early atherosclerotic cardiovascular disease (ASCVD).^[45] Other notable mutations include R496W, which resists furin cleavage and prolongs PCSK9 activity, and extracellular domain changes like L108R that enhance LDLR binding.^[46] Homozygous GOF cases are exceptionally rare; the first documented instance in 2015 involved compound heterozygosity leading to near-absent LDLR function and LDL-C levels above 20 mmol/L (772 mg/dL).^[47] PCSK9 GOF mutations account for less than 1-2% of genetically confirmed FH cases, with prevalence estimates ranging from 0.7% in large French cohorts to 1.8% in selected ADH screenings excluding common LDLR variants.^[45] ^[48] Affected individuals exhibit higher untreated LDL-C than those with LDLR or APOB mutations, along with a elevated risk of premature coronary artery disease, often manifesting before age 40, and classic FH stigmata such as corneal arcus and tendon xanthomas.^[46] Genetic testing for PCSK9 is recommended in FH patients negative for LDLR/APOB defects, particularly those with unusually high LDL-C or family history of early ASCVD, to guide intensified lipid-lowering therapy including PCSK9 inhibitors, which show pronounced efficacy in these carriers.^[22]

PCSK9 Levels as a Biomarker for Cardiovascular Risk

Plasma levels of PCSK9 positively correlate with low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B, and remnant cholesterol, reflecting its role in promoting LDL receptor degradation and impairing cholesterol clearance.^[49] In patients with coronary artery disease, circulating PCSK9 concentrations exceeding 431.3 ng/mL have been associated with heightened risk of acute coronary syndrome occurrence.^[49] These associations extend to subclinical atherosclerosis, where higher PCSK9 levels independently predict increased necrotic core volume in coronary plaques, a marker of plaque vulnerability.^[50] Prospective studies provide evidence for PCSK9 as a prognostic indicator in select populations. In the Swedish MONICA cohort, elevated baseline plasma PCSK9 levels forecasted incident atherosclerotic cardiovascular disease events over 15 years, independent of established risk factors including LDL-C.^[51] Among individuals with type 2 diabetes, sex-specific thresholds—299 ng/mL for women predicting major adverse cardiovascular events (odds ratio 2.26, 95% CI 1.12–4.58) and 244 ng/mL for men ≤75 years predicting all-cause mortality (hazard ratio 1.79, 95% CI 1.13–2.82)—persisted after adjustment for confounders such as age, HbA1c, statin use, and eGFR.^[49] In stable coronary heart disease patients with type 2 diabetes, higher serum PCSK9 correlated with disease severity and long-term cardiovascular event risk.^[52] Conversely, PCSK9's independent predictive value is not universal. In a nested case-control analysis from the Women's Health Study involving over 28,000 initially healthy women followed for 17 years, baseline PCSK9 levels across quartiles did not predict first cardiovascular events (odds ratios ranging from 0.94 to 1.15, P-trend=0.53), in contrast to apolipoprotein B which showed significant association.^[53] Such discrepancies highlight that PCSK9 may primarily signal risk through LDL-C mediation or in high-risk subgroups like those with diabetes or metabolic dysregulation, warranting context-specific application as a biomarker rather than broad screening.^[54]

Links to Inflammation, Fibrosis, and Non-CVD Conditions

PCSK9 has been implicated in promoting inflammatory processes beyond its primary role in lipid metabolism. Experimental studies demonstrate that PCSK9 enhances vascular inflammation by upregulating pro-inflammatory cytokines and contributing to atherosclerotic plaque instability, independent of LDL receptor degradation.^[55] ^[56] Inhibition of PCSK9 reduces expression of inflammatory proteins in carotid plaques and attenuates systemic inflammation in models of abdominal aortic aneurysm, without altering cholesterol levels.^[57] ^[58] Elevated circulating PCSK9 levels correlate with increased myocardial inflammation post-acute coronary events and higher major adverse cardiovascular event rates in diabetic patients with ST-elevation myocardial infarction.^[59] ^[60] Regarding fibrosis, PCSK9 drives fibrotic remodeling in multiple organs through activation of pathways such as TLR4/MyD88/NF-κB and JAK2/STAT3, leading to enhanced myofibroblast transformation and extracellular matrix deposition.^[61] ^[62] In cardiac tissue, PCSK9 exacerbates fibrogenesis by upregulating NLRP3 inflammasome signaling in fibroblasts.^[63] PCSK9 inhibition or genetic disruption alleviates pulmonary fibrosis-associated pulmonary hypertension via suppression of epithelial-mesenchymal transition and Wnt/β-catenin signaling, as well as renal fibrosis in lipid accumulation models.^[64] ^[65] Serum PCSK9 levels positively correlate with non-alcoholic fatty liver disease (NAFLD) fibrosis scores, suggesting a role in hepatic fibrogenesis.^[66] Lipid-lowering therapies targeting PCSK9 also mitigate airway hyperresponsiveness and lung fibrosis in obesity-related models through anti-inflammatory effects.^[67] In non-cardiovascular diseases, PCSK9 loss-of-function variants, which lower LDL cholesterol, associate with increased risks of type 2 diabetes and NAFLD, indicating potential adverse metabolic effects decoupled from lipid regulation.^[68] ^[69] PCSK9 inhibition shows promise in reducing inflammation during acute infections, such as SARS-CoV-2, by lowering IL-6 levels alongside LDL cholesterol.^[70] Among cancer survivors, PCSK9 inhibitor use correlates with reduced all-cause, cardiovascular, and cancer-related mortality, possibly via anti-inflammatory mechanisms.^[71] These associations highlight PCSK9's broader involvement in immune and fibrotic pathologies, warranting caution in therapeutic applications for non-lipid indications.

Therapeutic Inhibition

Monoclonal Antibodies: Development and Mechanisms

Monoclonal antibodies targeting PCSK9 represent a major advance in lipid-lowering therapy, developed after the discovery that PCSK9 gain-of-function mutations cause familial hypercholesterolemia and loss-of-function variants confer protection against coronary disease.^[72] The first fully human PCSK9 monoclonal antibodies, alirocumab (REGN727/Sanofi-Regeneron) and evolocumab (AMG 145/Amgen), entered phase 1 clinical trials in healthy volunteers around 2010-2011, demonstrating dose-dependent LDL-C reductions of up to 65% with subcutaneous administration.^[73] These agents progressed rapidly through phase 2 and 3 trials, culminating in FDA approvals in July 2015 for patients with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statins.^[74] Development focused on fully human IgG constructs to minimize immunogenicity, with alirocumab binding the catalytic domain of PCSK9 and evolocumab targeting a broader epitope to enhance potency.^[75] The mechanism of action involves neutralizing circulating PCSK9, a serine protease secreted primarily by hepatocytes, which normally binds the epidermal growth factor precursor homology domain of the LDL receptor (LDLR) on hepatocyte surfaces.^[76] This binding directs the LDLR-PCSK9 complex to lysosomes for degradation via clathrin-mediated endocytosis, reducing LDLR availability and impairing hepatic LDL-C clearance.^[75] By forming a high-affinity complex with PCSK9 (Kd ~ 10-100 pM for both antibodies), alirocumab and evolocumab prevent this interaction, allowing LDLR recycling to the cell surface and increasing receptor-mediated LDL uptake by 2-3 fold.^[77] The antibodies also accelerate PCSK9 clearance through receptor-mediated endocytosis independent of LDLR, further depleting extracellular PCSK9 levels by over 90% at therapeutic doses.^[72] This results in sustained LDL-C reductions of 50-70%, with effects persisting 2-4 weeks post-injection due to the antibodies' long half-life (~11-17 days).^[78] Unlike small molecules or RNA therapeutics, monoclonal antibodies act extracellularly without entering cells, avoiding off-target intracellular effects on PCSK9's role in protein processing.^[79] Phase 1 data confirmed specificity, with no significant impact on other convertases or prohormone processing.^[80] Both antibodies exhibit similar pharmacokinetics, achieving peak plasma concentrations within 3-7 days and steady-state inhibition after 2-3 doses, supporting dosing every two weeks or monthly for evolocumab.^[81]

RNA-Based Therapies: siRNA and Gene Silencing

Inclisiran is a synthetic small interfering RNA (siRNA) designed to silence hepatic PCSK9 gene expression by binding to PCSK9 mRNA, recruiting the RNA-induced silencing complex to cleave the target mRNA, and thereby reducing PCSK9 protein synthesis.^[82] This mechanism enhances low-density lipoprotein receptor (LDLR) recycling on hepatocyte surfaces, increasing LDL cholesterol (LDL-C) clearance from circulation without directly binding circulating PCSK9.^[83] Conjugated to N-acetylgalactosamine (GalNAc) for specific uptake by asialoglycoprotein receptors on hepatocytes, inclisiran achieves prolonged silencing with subcutaneous dosing: 284 mg initially, at 3 months, and every 6 months thereafter.^[84] Developed by Alnylam Pharmaceuticals and Novartis, inclisiran progressed through phase 3 ORION trials demonstrating consistent LDL-C reductions of approximately 50% from baseline at day 510 in patients with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) on maximally tolerated statins.^[85] In ORION-10 (n=1,617), inclisiran yielded a 52.3% mean reduction (95% CI: 48.8-55.7%); ORION-11 (n=1,621) showed 49.9% (95% CI: 46.6-53.2%).^[85] ORION-9 specifically in HeFH (n=482) confirmed 47.9% reduction, with additive effects alongside statins and ezetimibe.^[86] Long-term extensions, including ORION-8 (n=3,274, up to 4 years) and ORION-3, maintained ~50% LDL-C lowering with twice-yearly dosing, alongside reductions in PCSK9 levels by 60-70% and non-HDL-C by 45-50%.^[87] ^[88] Safety profiles from pooled ORION data (over 3,500 patients, mean exposure 2.8 years) indicate inclisiran is well-tolerated, with primary adverse events being mild injection-site reactions (8-10% incidence, resolving quickly) and no excess in serious events like myopathy, hepatic enzyme elevations, or neurocognitive issues compared to placebo.^[89] ^[90] Regulatory approvals followed: European Union in December 2020 for primary hypercholesterolemia or mixed dyslipidemia in adults at high CV risk, and U.S. FDA in December 2021 for adults with HeFH or ASCVD requiring LDL-C lowering.^[91] ^[92] Beyond inclisiran, other RNA-based PCSK9 silencing approaches remain preclinical or early-stage, including antisense oligonucleotides (e.g., mipomersen analogs) and novel RNAi constructs like polypurine reverse Hoogsteen hairpins, which demonstrated in vitro PCSK9 knockdown but lack clinical validation.^[93] ^[94] No additional siRNA therapies have achieved approval as of 2025, positioning inclisiran as the sole clinically established option for durable, infrequent gene silencing in PCSK9-targeted lipid management.^[11]

Emerging Oral Small-Molecule Inhibitors

Oral small-molecule inhibitors of PCSK9 represent a promising advancement over injectable monoclonal antibodies and RNA therapies, offering potential for improved patient adherence through once-daily dosing without the need for refrigeration or injections.^[95] These agents aim to block PCSK9's interaction with the LDL receptor (LDLR), thereby increasing hepatic LDLR availability and enhancing LDL cholesterol (LDL-C) clearance.^[96] Unlike biologics, small molecules can be designed for oral bioavailability, addressing limitations in accessibility and convenience.^[97] Merck's enlicitide decanoate (MK-0616), a macrocyclic peptide PCSK9 inhibitor, has advanced to phase 3 trials for hypercholesterolemia. In the CORALreef Lipids study, completed in September 2025, enlicitide met all primary and key secondary endpoints, achieving statistically significant LDL-C reductions of up to 60% as monotherapy and additional 50% when added to statins in adults with elevated LDL-C. The CORALreef HeFH trial similarly demonstrated efficacy in patients with heterozygous familial hypercholesterolemia, with primary completion in September 2025.^[98] Phase 2 data from 2023 showed dose-dependent LDL-C lowering of 40-65% over 8 weeks, with a favorable safety profile and no significant hepatic or muscle-related adverse events beyond placebo rates.^[99] If approved, enlicitide would be the first oral PCSK9 inhibitor, potentially transforming lipid management for high-risk patients.^[100] AstraZeneca's AZD0780, a once-daily oral small-molecule PCSK9 inhibitor, demonstrated significant LDL-C reductions in the phase 2b PURSUIT trial reported on March 31, 2025. In patients on stable rosuvastatin 20 mg, AZD0780 doses of 2-15 mg reduced LDL-C by 35-51% from baseline over 12 weeks, compared to 2% with placebo, with dose-proportional pharmacokinetics and no new safety signals.^[101] ^[95] Phase 1 studies confirmed up to 51% additional LDL-C lowering on top of high-dose statins, supporting its potential for patients not achieving goals with standard care.^[102] Ongoing development focuses on optimization for broader cardiovascular risk reduction.^[103] Preclinical efforts, such as Novartis's NYX-PCSK9i, have identified orally bioavailable small molecules that inhibit PCSK9-mediated LDLR degradation in animal models, achieving substantial cholesterol lowering without immunogenicity concerns associated with peptides.^[104] Challenges remain in achieving sufficient potency and selectivity to match injectable therapies' efficacy, with liver enzyme elevations and gastrointestinal tolerability under evaluation in early trials.^[96] Long-term cardiovascular outcomes data are pending from ongoing studies, but these inhibitors could expand PCSK9 targeting to primary prevention and underserved populations.^[97]

Efficacy and Clinical Evidence

LDL-C Reduction and Cardiovascular Outcome Trials

The FOURIER trial evaluated evolocumab, a monoclonal antibody inhibitor of PCSK9, in 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD) receiving maximally tolerated statin therapy, with baseline LDL-C levels of at least 70 mg/dL (1.8 mmol/L).^[105] Evolocumab reduced LDL-C by an average of 59% from baseline (from 92.0 mg/dL to 30.0 mg/dL at 48 weeks), achieving mean levels of 30 mg/dL over the median follow-up of 2.2 years.^[105] The primary endpoint—a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization—was reduced by 20% (hazard ratio [HR] 0.80; 95% CI, 0.73 to 0.88; p<0.001), with 1,344 events in the evolocumab group versus 1,563 in placebo.^[105] The key secondary endpoint (cardiovascular death, myocardial infarction, or stroke) showed a 21% reduction (HR 0.79; 95% CI, 0.71 to 0.89; p<0.001).^[105] No significant difference was observed in cardiovascular mortality alone (HR 1.02; 95% CI, 0.84 to 1.22).^[105] Benefits were consistent across subgroups, including those with baseline LDL-C below 70 mg/dL, supporting incremental risk reduction with deeper LDL-C lowering.^[106] The ODYSSEY OUTCOMES trial assessed alirocumab in 18,924 patients 1 to 12 months post-acute coronary syndrome, on maximally tolerated lipid-lowering therapy with LDL-C ≥70 mg/dL.^[107] Alirocumab, administered subcutaneously every two weeks with dose adjustment to target LDL-C 25-50 mg/dL, lowered LDL-C by a mean of 54.7 mg/dL from baseline (from 101.3 mg/dL to 53.3 mg/dL at week 4, sustained to 40.0 mg/dL by month 4).^[107] Over a median follow-up of 2.8 years, the primary endpoint—composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization—was reduced by 15% (HR 0.85; 95% CI, 0.78 to 0.93; p<0.001), with 911 events in the alirocumab group versus 1,052 in placebo.^[107] All-cause mortality was also reduced by 15% (HR 0.85; 95% CI, 0.73 to 0.98; p=0.026), driven by fewer cardiovascular deaths.^[107] Post-hoc analyses confirmed fewer total (first and recurrent) nonfatal cardiovascular events and deaths (385 fewer events; rate ratio 0.80; p<0.001).^[108] Efficacy was greater in patients with baseline LDL-C ≥100 mg/dL and those not achieving low levels on statins alone.^[107] These trials demonstrate that PCSK9 inhibition yields LDL-C reductions of 50-60% beyond statin therapy, translating to proportional decreases in major adverse cardiovascular events, with absolute risk reductions of 1-2% over 2-3 years in high-risk populations.^[109] Both studies align with Mendelian randomization evidence linking genetically lower LDL-C to reduced ASCVD risk, reinforcing causality independent of on-treatment levels achieved.^[110] However, the SPIRE trials with bococizumab (another PCSK9 inhibitor) were terminated early due to waning efficacy from anti-drug antibodies, limiting broader applicability.^[106] Long-term open-label extensions from FOURIER and ODYSSEY suggest sustained LDL-C control and event rate divergence beyond trial durations, though definitive mortality benefits require further data.^[111]

Impacts on Mortality, Safety Profiles, and Long-Term Data

In pivotal cardiovascular outcome trials, PCSK9 inhibitors demonstrated varied impacts on mortality. The FOURIER trial, evaluating evolocumab in 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD), reported no significant reduction in all-cause mortality (hazard ratio [HR] 1.02, 95% CI 0.87-1.20) or cardiovascular mortality (HR 1.05, 95% CI 0.85-1.29) over a median follow-up of 2.2 years, despite a 20% relative risk reduction in the primary composite endpoint of cardiovascular death, myocardial infarction, or stroke.^[105] In contrast, the ODYSSEY OUTCOMES trial of alirocumab in 18,924 patients post-acute coronary syndrome found a significant 15% reduction in all-cause mortality (HR 0.85, 95% CI 0.73-0.98) after a median 2.8 years, with benefits accruing after at least 3 years of therapy and particularly in those achieving LDL-C below 50 mg/dL.^[112] Meta-analyses of randomized trials have yielded inconsistent results, with some showing no overall mortality benefit (odds ratio [OR] 0.96, 95% CI 0.82-1.12 for all-cause death) and others, including real-world comparisons to statins, indicating reductions in all-cause mortality (e.g., HR 0.78 in dyslipidemia cohorts).^[113]^[114] Genetic studies support a causal link, as lifelong PCSK9 loss-of-function variants correlate with lower cardiovascular mortality rates, though short-term trial durations limit direct translation.^[115] Safety profiles of PCSK9 inhibitors are generally favorable, with low rates of serious adverse events comparable to placebo in phase 3 trials and meta-analyses. Common adverse events include injection-site reactions (5-10% incidence), nasopharyngitis, and upper respiratory infections, leading to discontinuation in 1-2% of patients; muscle-related events occur less frequently than with high-intensity statins.^[116]^[117] Neurocognitive adverse events, a theoretical concern due to LDL-C lowering, showed no significant increase (OR 1.12, 95% CI 0.78-1.61) in pooled analyses of over 30 trials, and recent long-term cognitive assessments confirmed no impairment.^[118] Ophthalmic events like cataracts were not elevated, though creatine kinase elevations occurred more often (OR 1.51, 95% CI 1.02-2.23).^[119] Controversies include potential underreporting in trials; one reanalysis of FOURIER mortality data alleged misclassification, suggesting numerically higher cardiac deaths with evolocumab (113 vs. 88 in placebo), though trial investigators disputed this, attributing differences to adjudication standards.^[120] Long-term data from open-label extensions and real-world registries affirm sustained efficacy and tolerability. In FOURIER's open-label extension (up to 8.4 years total exposure), evolocumab maintained LDL-C reductions of 55-60% with fewer cardiovascular events and no excess serious adverse events, including stable rates of new-onset diabetes.^[111] Similarly, pooled alirocumab data from 47,296 patient-years showed consistent safety, with adverse event rates mirroring shorter trials and no signals for malignancy or infection excess.^[121] Real-world pharmacovigilance analyses confirm lower muscle toxicity versus statins or ezetimibe, though type 2 diabetes risk may rise modestly with prolonged use, akin to genetic PCSK9 inhibition effects (OR 1.28 per 1 SD LDL-C reduction).^[122]^[117] Ongoing registries report adherence challenges due to subcutaneous administration but sustained LDL-C lowering in high-risk cohorts, with overall adverse event incidence around 75% (mostly mild).^[123] These findings underscore safety in extended use, though diabetes monitoring is warranted given mechanistic parallels to intensive lipid lowering.^[124]

Controversies and Limitations

Discrepancies in Trial Outcomes and Data Interpretation

Clinical trials of PCSK9 inhibitors have demonstrated consistent reductions in low-density lipoprotein cholesterol (LDL-C) levels by 50-60%, yet the magnitude of cardiovascular event reduction has often fallen short of predictions based on prior lipid-lowering therapies and genetic studies. For instance, in the FOURIER trial of evolocumab, a 59% LDL-C reduction correlated with only a 20% relative reduction in major adverse cardiovascular events (MACE), less than the proportional benefit anticipated from statin trials or Mendelian randomization analyses, which suggest approximately 20-25% risk reduction per 1 mmol/L (39 mg/dL) LDL-C decrement.^[125] Similar attenuation was observed in the SPIRE trials of bococizumab, where initial LDL-C lowering waned over time due to immunogenicity and anti-drug antibodies, resulting in no significant MACE reduction in the primary prevention-like SPIRE-1 cohort and only modest benefits in the higher-risk SPIRE-2 group before early termination.^[126] These outcomes contrast with the more sustained effects of fully humanized monoclonal antibodies like alirocumab in ODYSSEY OUTCOMES, highlighting drug-specific differences in durability and efficacy.^[127] Interpretation of trial data has sparked debate over endpoint hierarchies and surrogate reliance. While FOURIER and ODYSSEY OUTCOMES reported significant MACE reductions (20% and 15%, respectively), neither achieved statistical significance for all-cause mortality (FOURIER HR 0.85, 95% CI 0.73-1.00; ODYSSEY similar nonsignificant trend), prompting questions about whether LDL-C lowering alone guarantees hard outcome benefits when added to high-intensity statins.^[128] Meta-analyses reinforce this, showing consistent MACE benefits but no overall mortality improvement across PCSK9 inhibitor trials involving over 60,000 patients.^[129] Reanalyses of FOURIER mortality data have alleged potential misclassification of cardiovascular versus noncardiovascular deaths, suggesting a possible null or adverse signal under alternative adjudication, though trial investigators disputed these claims citing blinded, predefined criteria.^[130] ^[131] Such discrepancies underscore challenges in interpreting composite endpoints, where reductions in nonfatal events (e.g., myocardial infarction, stroke) drive significance without corresponding mortality gains, potentially inflating perceived benefits relative to absolute risk reductions of 1-2% over trial durations.^[132] Subgroup and trial design variations further complicate data synthesis. ODYSSEY OUTCOMES, conducted in recent acute coronary syndrome patients, showed hints of all-cause mortality reduction (HR 0.85) and unstable angina benefits absent in the more stable FOURIER population, possibly reflecting differences in baseline risk or event timing.^[132] Bococizumab's immunogenicity—leading to 10-15% antibody formation and LDL-C rebound—exemplifies how pharmacological properties can undermine class-wide assumptions, as evidenced by higher discontinuation rates (up to 13%) versus <1% for evolocumab.^[126] Critics argue that overreliance on industry-sponsored trials, with their focus on relative risk reductions, may overlook absolute benefits in context of high costs and injection burdens, while proponents emphasize consistency with lipid hypothesis predictions despite shorter follow-up compared to statin megatrials.^[125] These interpretive tensions highlight the need for longer-term, head-to-head data to resolve whether observed discrepancies stem from trial artifacts, patient selection, or limitations in extrapolating LDL-C as a causal proxy.

Adverse Events, Cost-Effectiveness, and Access Barriers

Monoclonal antibodies targeting PCSK9, such as alirocumab and evolocumab, exhibit a favorable safety profile in clinical trials and real-world data, with the most common adverse events being mild and including injection-site reactions (affecting 5-10% of patients), nasopharyngitis, and upper respiratory tract infections.^[133] ^[116] Serious adverse events are infrequent, occurring at rates comparable to placebo or statin controls, and long-term follow-up from trials like FOURIER and ODYSSEY OUTCOMES (extending up to 5 years) confirms sustained tolerability without evidence of increased malignancy, hepatic, or renal toxicity.^[121] ^[124] Potential concerns include neurocognitive effects due to profound LDL-C reduction, but a 2024 analysis of evolocumab data found no clinically meaningful impairment in cognitive function over 8 years, aligning with genetic studies showing no causal link between lifelong low LDL-C and dementia risk.^[134] Real-world pharmacovigilance from the FDA Adverse Event Reporting System (2003-2021) identified signals for musculoskeletal disorders (reporting odds ratio 1.2-1.5), though causality remains unconfirmed and rates do not exceed background statin use.^[117] Mendelian randomization studies suggest a modest association with type 2 diabetes risk (odds ratio ~1.1 per 1 mmol/L LDL-C lowering), similar to high-intensity statins, but without excess infections or immune dysregulation.^[122] ^[135] Overall, meta-analyses of over 50,000 patients report no significant increase in discontinuations due to adverse events compared to standard therapy (odds ratio 1.05, 95% CI 0.95-1.16).^[136] Cost-effectiveness analyses indicate PCSK9 inhibitors yield incremental cost-effectiveness ratios (ICERs) exceeding $100,000 per quality-adjusted life-year (QALY) in many U.S. and European models when added to maximally tolerated statins, particularly for primary prevention or younger patients with familial hypercholesterolemia.^[137] Manufacturer price reductions of 60% in 2018 improved affordability, yet mean annual costs remain ~$8,500 per patient versus $3,800 for statin-ezetimibe combinations, limiting value in secondary prevention unless LDL-C targets (<55 mg/dL) are unmet.^[138] ^[139] For high-risk secondary prevention, ICERs drop below $50,000/QALY with negotiated discounts, outperforming ezetimibe alone but trailing generic statins; however, statin-ezetimibe remains more economical overall due to lower acquisition costs and comparable event reduction in moderate-risk groups.^[140] ^[141] In young adults with LDL-C ≥190 mg/dL, prices would require a further 61% reduction for high cost-effectiveness (<$50,000/QALY).^[142] Access barriers persist despite efficacy, primarily from stringent prior authorization (PA) requirements imposed by 82-97% of U.S. health plans, often mandating documentation of statin intolerance, LDL-C >100-130 mg/dL on therapy, or recent acute coronary events, leading to denial rates of 40-60%.^[143] ^[144] High out-of-pocket costs ($1,000-5,000 annually post-insurance) and administrative burdens deter prescriptions, with only 10-20% of eligible patients initiating therapy in real-world cohorts.^[145] ^[146] These hurdles disproportionately affect underserved populations, exacerbating disparities in lipid management, though specialty pharmacy navigation and appeals can improve uptake by 20-30%.^[147] ^[148]

Future Prospects

Ongoing Trials and Novel Approaches

Ongoing clinical trials are evaluating oral PCSK9 inhibitors as alternatives to injectable therapies, aiming to improve patient adherence through convenient dosing. Merck's enlicitide decanoate, an investigational oral macrocyclic peptide PCSK9 inhibitor, met primary and key secondary endpoints in the phase 3 CORALREEF Lipids trial, demonstrating statistically significant LDL-C reductions of up to 62% when added to statins in adults with hypercholesterolemia.^[149] Similarly, AstraZeneca's AZD0780, a once-daily oral small-molecule PCSK9 inhibitor, achieved dose-dependent LDL-C reductions of 30-55% in the phase 2b PURSUIT trial among patients not at LDL-C goals on standard lipid-lowering therapy.^[101]^[95] These trials highlight progress toward antibody-like efficacy with oral formulations, though long-term cardiovascular outcomes remain under investigation.^[150] Gene-editing strategies represent novel approaches for durable PCSK9 inhibition, potentially offering one-time treatments. Verve Therapeutics is advancing VERVE-101, an adenine base editor delivered via lipid nanoparticles to inactivate the PCSK9 gene in hepatocytes, with phase 1b Heart-2 trial data reported in early 2025 showing safe editing in patients with heterozygous familial hypercholesterolemia.^[151] An epigenetic editor targeting PCSK9 for promoter DNA methylation achieved sustained gene silencing in preclinical models, reducing PCSK9 protein by over 90% and LDL-C by 50-70% for months post-administration.^[152] Additionally, polypurine reverse Hoogsteen hairpins, a DNA-based silencing system, inhibited PCSK9 expression in vitro and in animal models, yielding nearly 50% LDL-C reductions without reliance on viral vectors or statins.^[153]^[93] These methods prioritize liver-specific targeting to minimize off-target effects, though clinical translation requires further safety validation in humans.^[154] Combination therapies and expanded indications are also in exploration. Phase 3 outcome trials like VESALIUS-CV for evolocumab continue to assess PCSK9 inhibition in primary prevention, confirming event reductions in broad populations.^[155] Preclinical work investigates PCSK9 modulation beyond lipid lowering, such as in neuroinflammation, but human evidence is preliminary.^[156] Overall, these developments emphasize scalability and permanence, with oral agents addressing adherence barriers and editing tools promising lifelong efficacy, pending regulatory scrutiny of durability and immunogenicity.^[94]^[157]

Potential Applications Beyond Lipid Management

PCSK9, beyond its canonical role in hepatic LDL receptor degradation, is expressed in extrahepatic tissues including the brain, kidneys, and immune cells, where it modulates inflammation, oxidative stress, and cellular trafficking processes.^[11] Inhibition of PCSK9 has shown preclinical promise in non-lipid disorders by enhancing receptor-mediated clearance mechanisms and altering immune responses, though human evidence remains limited to observational or genetic studies rather than dedicated trials.^[158] In infectious diseases, particularly sepsis, circulating PCSK9 levels rise acutely and correlate with 28-day mortality risk, with thresholds above 370 ng/mL indicating poorer outcomes.^[159] Preclinical models suggest PCSK9 inhibition could improve bacterial and viral clearance by upregulating LDL receptors on macrophages and hepatocytes, facilitating endocytosis of lipopolysaccharide (LPS) and pathogens like E. coli or Ebola virus.^[160] However, meta-analyses of clinical data from PCSK9 inhibitor trials (e.g., evolocumab, alirocumab) report no significant reduction in sepsis incidence or severe infections compared to placebo, with hazard ratios near 1.0 across cardiovascular outcome studies involving over 50,000 patients.^[161]^[162] Genetic variants lowering PCSK9 activity also show no protective association against sepsis hospitalization.^[163] Emerging evidence implicates PCSK9 in neurodegenerative conditions like Alzheimer's disease (AD), where it promotes amyloid-beta (Aβ) accumulation, blood-brain barrier disruption, and neuroinflammation via oxidative stress and microglial activation.^[158] In 5XFAD mouse models of AD, PCSK9 knockout reduces Aβ plaque burden, attenuates microgliosis, and improves cognitive performance, as measured by Morris water maze tasks.^[164] Pharmacological inhibition with small molecules protects neuronal cultures from Aβ-induced toxicity in vitro, suggesting a direct neuroprotective mechanism independent of lipid effects.^[165] Peripheral PCSK9 blockade in rodent models increases cerebral Aβ clearance via enhanced LDL receptor expression on brain endothelial cells.^[166] Mendelian randomization studies link lifelong PCSK9 inhibition to neutral effects on AD biomarkers like tau or amyloid PET imaging, with no elevated dementia risk, though dedicated cognitive trials in AD patients are absent.^[167]^[168] In oncology, PCSK9 inhibition enhances anti-tumor immunity by preventing lysosomal degradation of MHC class I molecules on cancer cells, thereby increasing antigen presentation to cytotoxic T cells.^[169] Mouse models of melanoma and sarcoma demonstrate that PCSK9 knockout or antibody blockade synergizes with anti-PD-1 therapy, reducing tumor growth by 50-70% and boosting CD8+ T-cell infiltration.^[169]^[170] In head and neck squamous cell carcinoma, elevated PCSK9 correlates with stemness and poor prognosis; its inhibition curbs epithelial-mesenchymal transition and sensitizes cells to immunotherapy.^[171] Contrasting data indicate PCSK9 may promote metastasis in colon and breast cancers via PI3K/AKT signaling, complicating its role.^[172] No large-scale trials test PCSK9 inhibitors as adjuncts in cancer, but preclinical synergy supports exploration in cholesterol-independent contexts.^[173]

References

[1]
PCSK9 proprotein convertase subtilisin/kexin type 9 [ (human)] - NCBI
Sep 9, 2025 · The mutational spectrum of familial hypercholesterolemia due to LDLR; APOB and PCSK9 mutations is still growing, but there is also increasing ...
[2]
PCSK9 gene: MedlinePlus Genetics
Jan 1, 2020 · Researchers have identified more than 50 PCSK9 gene mutations that cause familial hypercholesterolemia. Most of these mutations change ...
[3]
PCSK9 function and physiology - PMC - NIH
PCSK9 regulates the levels of the LDL receptor (1–3), which is a plasma membrane glycoprotein that removes cholesterol-rich LDL particles from the plasma (4, 5) ...
[4]
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
May 5, 2003 · Thus, mutations in PCSK9 have been found in 12.5% of the families with ADH that we tested. We also identified 25 polymorphisms present in ...<|separator|>
[5]
PCSK9 gene mutations and low-density lipoprotein cholesterol
Apr 20, 2014 · It has been demonstrated that PCSK9 gene mutations are associated with hyper- or hypocholesterolemia. In the latter case, the incidence of coronary heart ...
[6]
PROPROTEIN CONVERTASE, SUBTILISIN/KEXIN-TYPE, 9; PCSK9
Selected missense mutations in the PCSK9 gene cause autosomal dominant hypercholesterolemia (e.g., 607786.0001), whereas nonsense mutations in the same gene ...
[7]
PCSK9 Inhibitors: The Evolving Future - PMC - NIH
Nov 29, 2024 · Clinical trials have shown PCSK9 inhibitors reduce LDL‐C by up to 60%. In the FOURIER trial, evolocumab reduced LDL‐C by 59% and major ...
[8]
PCSK9: From Basic Science Discoveries to Clinical Trials - PMC
Here, we review major scientific understandings as they relate to the role of PCSK9 in lipoprotein metabolism and atherosclerotic cardiovascular disease.
[9]
The Evolving Future of PCSK9 Inhibitors - JACC
Clinical trials with PCSK9 inhibitors have demonstrated reductions in atherosclerotic cardiovascular disease events, particularly in patients with recent acute ...<|control11|><|separator|>
[10]
The Multifaceted Biology of PCSK9 - PMC - PubMed Central - NIH
This article reviews the discovery of PCSK9, its structure–function characteristics, and its presently known and proposed novel biological functions.
[11]
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9)
Jan 8, 2024 · This comprehensive review delineates the intricate roles and wide-ranging implications of PCSK9, extending beyond CVD to emphasize its significance in diverse ...
[12]
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
We mapped a third locus associated with ADH, HCHOLA3 at 1p32, and now report two mutations in the gene PCSK9 (encoding proprotein convertase subtilisin/kexin ...Missing: studies | Show results with:studies
[13]
The PCSK9 discovery, an inactive protease with varied functions in ...
In this review, we present the critical information that led to the discovery of PCSK9 and its implication in LDL-C metabolism.
[14]
PCSK9 | Circulation Research - American Heart Association Journals
Mar 14, 2014 · Since the discovery of proprotein convertase subtilisin kexin 9 (PCSK9) in 2003, this PC has attracted a lot of attention from the ...
[15]
PCSK9: From Discovery and Validation to Therapy
May 14, 2014 · In 2003, Abifadel and coworkers identified a gain of function mutation in the gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) ...<|separator|>
[16]
Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA ...
On July 24, 2015, the US Food and Drug Administration (FDA) approved alirocumab (Praluent; Sanofi), the first proprotein convertase subtilisin kexin 9 (PCSK9) ...
[17]
Repatha (evolocumab) FDA Approval History - Drugs.com
Aug 26, 2025 · Jul 11, 2016, Approval FDA Approves Repatha (evolocumab) Pushtronex - First And Only Single Monthly Injection for a PCSK9 Inhibitor ; Aug 27, ...
[18]
PCSK9: From Nature's Loss to Patient's Gain | Circulation
Jan 16, 2024 · In 2003, Abifadel et al identified missense mutations in PCSK9 that cause autosomal dominant hypercholesterolemia. It was unclear whether the ...
[19]
Gene: PCSK9 (ENSG00000169174) - Summary - Homo_sapiens
Chromosome 1: 55,039,445-55,064,852 forward strand. This gene has 12 transcripts (splice variants), 158 orthologues, 9 paralogues and is associated with 2 ...
[20]
PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular ...
The best-known function of PCSK9 is its effect on low density lipoprotein receptor (LDLR), to which it can bind and thereby facilitate its lysosomal degradation ...
[21]
Molecular population genetics of PCSK9: a signature of recent ... - NIH
(a) Structure of PCSK9. ... Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy.
[22]
PCSK9 Variants in Familial Hypercholesterolemia - PubMed Central
Sep 23, 2020 · Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.
[23]
Association of PCSK9 Variants With the Risk of Atherosclerotic ...
An E670G polymorphism of the PCSK9 gene was recently found to be associated with increased plasma LDL-C levels and the risk of coronary atherosclerosis in a ...
[24]
Polymorphisms of rs2483205 and rs562556 in the PCSK9 gene are ...
Jun 1, 2021 · Studies have indicated that variants in PCSK9 are independently associated with cardiovascular events through their effects on LDL-C levels; ...
[25]
PCSK9 Variants in Familial Hypercholesterolemia - Frontiers
Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.
[26]
Multifaceted Biology of PCSK9 | Endocrine Reviews | Oxford Academic
This article reviews the discovery of PCSK9, its structure–function characteristics, and its presently known and proposed novel biological functions.
[27]
The self-inhibited structure of full-length PCSK9 at 1.9 Å ... - PNAS
The structure of PCSK9 provides valuable insight into its specificity and function and the structural relationship to other cellular proteins involved in ...<|separator|>
[28]
The Crystal Structure of PCSK9: A Regulator of Plasma LDL ...
Mar 10, 2007 · The crystal structure reveals that PCSK9 has subtilisin-like pro- and catalytic domains, and a novel C-terminal domain (termed V domain) (Figure ...<|control11|><|separator|>
[29]
The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol
PCSK9 has subtilisin-like pro- and catalytic domains, and the stable interaction between these domains prevents access to PCSK9's catalytic site. The C-terminal ...
[30]
2P4E: Crystal Structure of PCSK9 - RCSB PDB
Apr 10, 2007 · The structure of human PCSK9 shows the subtilisin-like catalytic site blocked by the prodomain in a noncovalent complex and inaccessible to exogenous ligands.
[31]
Point mutations at the catalytic site of PCSK9 inhibit folding ...
Point mutations at the catalytic site of PCSK9 inhibit folding, autoprocessing, and interaction with the LDL receptor - PMC.
[32]
Molecular basis for LDL receptor recognition by PCSK9 - PNAS
The C-terminal domain of PCSK9 contains three six-stranded β-sheet subdomains arranged with quasi-threefold symmetry. This domain shares structural homology to ...Results And Discussion · Mutagenesis Of Pcsk9 · Pcsk9-Dependent Ldlr...
[33]
3P5C: The structure of the LDLR/PCSK9 complex ... - RCSB PDB
Oct 26, 2011 · The structure shows LDLR in a new extended conformation. The PCSK9 C-terminal domain is solvent exposed, enabling cofactor binding, whereas the ...
[34]
PCSK9: a convertase that coordinates LDL catabolism - PMC
PCSK9 is a secreted protease that mediates degradation of the LDL receptor by interacting with the extracellular domain and targeting the receptor for ...
[35]
PCSK9 and LDLR degradation: regulatory mechanisms in ...
Purpose of review. Proprotein convertase subtilisin/kexin type-9 (PCSK9) binds to LDL receptor (LDLR) and targets it for lysosomal degradation in cells.
[36]
Molecular biology of PCSK9: its role in LDL metabolism - PMC - NIH
Proprotein convertase subtilisin-like kexin type 9 (PCSK9) is a newly discovered serine protease that destroys low density lipoprotein (LDL) receptors in ...
[37]
The PCSK9 decade: Thematic Review Series: New Lipid and ... - NIH
PCSK9 proprotein convertase subtilisin/kexin type (PCSK9) is a crucial protein in LDL cholesterol (LDL-C) metabolism by virtue of its pivotal role in the ...<|separator|>
[38]
PCSK9 and Lipid Metabolism - PMC - NIH
PCSK9 blocks LDLR recycling, reducing LDL-C uptake and increasing plasma LDL-C, thus playing a role in cholesterol homeostasis.
[39]
On the Function and Homeostasis of PCSK9: Reciprocal Interaction ...
Dec 17, 2014 · (3) PCSK9 down-regulates cell surface LDLR by targeting it to lysosomal degradation. (4) Loss of LDLR increases intracellular apoB protein ...
[40]
Physiological and therapeutic regulation of PCSK9 activity in ...
In this review, we summarize and discuss the recent biological and clinical data on PCSK9, the regulation of PCSK9, its extra-hepatic activities focusing on ...
[41]
Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin ...
Dec 7, 2020 · However, PCSK9 is almost ubiquitously expressed in the body but has less well-understood functions and target proteins in extra hepatic tissues.
[42]
https://journals.lww.com/co-lipidology/fulltext/2015/06000/Role_of_PCSK9_beyond_liver_involvement.2.aspx
[43]
Pleiotropy of PCSK9: Functions in Extrahepatic Tissues - PubMed
Purpose of review: Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a central role in the metabolism of LDL receptors and mainly acts in the liver.
[44]
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in the Brain ...
Jun 12, 2020 · PCSK9 has been shown to be involved in neuronal differentiation, LDL receptor family metabolism, apoptosis, and inflammation in the brain.
[45]
PCSK 9 gain-of-function mutations (R496W and D374Y) and clinical ...
More than 30 PCSK9 gain-of-function (GOF) mutations have been reported to be the cause of FH since the discovery of PCSK9 in 2003 (5, 6).
[46]
Characterization of Autosomal Dominant Hypercholesterolemia ...
Gain of mutation mutations in the PCSK9 gene lead to a rare form of autosomal dominant hypercholesterolemia. However, clinical data on this condition are scarce ...
[47]
Characterization of the First PCSK9 Gain of Function Homozygote
Nov 2, 2015 · Gain of function (GOF) mutations in proprotein convertase subtilisin kexin type 9 (PCSK9) are a rare cause of familial hypercholesterolemia ...
[48]
Identification and in vitro characterization of two new PCSK9 Gain of ...
Nov 10, 2017 · Among PCSK9 variants, only Gain-of- Function (GOF) variants lead to FH. Greater attention should be paid to the classification of variants as ...
[49]
Circulating PCSK9 as a prognostic biomarker of cardiovascular ...
Aug 24, 2023 · Specifically, PCSK9 values > 431.3 ng/mL were correlated with a higher risk of occurrence of ACS [32]. In patients with coronary artery disease ...
[50]
https://doi.org/10.1016/j.atherosclerosis.2016.03.010
[51]
https://doi.org/10.1161/CIRCULATIONAHA.115.018531
[52]
Association between serum PCSK9 and coronary heart disease in ...
Dec 20, 2023 · This study aims to investigated serum PCSK9 levels and severity of CHD in stable CHD patients with T2DM, as well as the risk of long-term cardiovascular events.
[53]
Plasma proprotein convertase subtilisin/kexin type 9 ... - PubMed - NIH
Feb 7, 2016 · ... plasma PCSK9 levels predict incident cardiovascular events. Methods and results: In a nested case-control evaluation conducted in a prospective ...
[54]
PCSK9 | Circulation Research - American Heart Association Journals
Therapeutic PCSK9 inhibition in humans only significantly reduces LDL-C levels after 2 to 3 days from start of therapy. Based on these observations, it is clear ...Missing: original paper
[55]
PCSK9 and inflammation: a review of experimental and clinical ...
Oct 1, 2019 · In this review, we represent mounting evidence indicating that PCSK9 can locally increase vascular inflammation and contribute to atherosclerotic plaque ...
[56]
PCSK9 and inflammation: a review of experimental and clinical ...
In this review, we represent mounting evidence indicating that PCSK9 can locally increase vascular inflammation and contribute to atherosclerotic plaque ...Introduction · Epidemiological evidence... · PCSK9 inhibitors and vascular...
[57]
Disruption of PCSK9 Suppresses Inflammation and Attenuates ...
Nov 26, 2024 · Pcsk9 deletion attenuated AAA formation, improved survival, and decreased systemic inflammation, without altering circulating cholesterol levels.Pcsk9 Expression In Human... · Pcsk9 Deletion Attenuated... · Pcsk9 Inhibition Constrained...
[58]
Evidence of an anti-inflammatory effect of PCSK9 inhibitors within ...
Jun 29, 2023 · Patients on therapy with PCSK9 inhibitors have a lower burden of inflammatory proteins within the carotid plaque.
[59]
Impact of In-Hospital PCSK9 Inhibition on Myocardial Inflammation ...
May 29, 2025 · PCSK9 levels at 30 days were significantly associated with myocardial inflammation and we observed a modest association between PCSK9 levels and ...
[60]
Association of PCSK9 with inflammation and platelet activation ...
May 20, 2022 · Conclusions: The study showed that high PCSK9 levels were independently associated with MACEs in STEMI patients with diabetes undergoing primary ...
[61]
PCSK9 Enhances Cardiac Fibrogenesis via the Activation of Toll ...
In conclusion, PCSK9 upregulates NLRP3 signaling and the profibrotic activities of cardiac fibroblasts through the activation of TLR4/Myd88/NF-κB signaling.
[62]
PCSK9 regulates myofibroblast transformation through the JAK2 ...
This study suggests that PCSK9 may function as a novel regulator of myocardial fibrosis, primarily via the JAK2/STAT3 pathway.
[63]
PCSK9 Enhances Cardiac Fibrogenesis via the Activation of Toll ...
Feb 23, 2025 · PCSK9 activates the atherosclerosis process through pro-inflammation signaling. Furthermore, the serum level of PCSK9 is positively correlated ...
[64]
PCSK9 inhibitor alleviates experimental pulmonary fibrosis-induced ...
Dec 11, 2024 · PCSK9 plays a crucial role in the progression of PF-induced PH by regulating cell EMT and Wnt/β-catenin signaling.
[65]
Vaccine Against PCSK9 Improved Renal Fibrosis by Regulating ...
Dec 24, 2019 · It is remarkable that immunization of the PCSK9 Qβ‐003 vaccine significantly improved renal lipid accumulation and attenuated the development ...
[66]
NAFLD fibrosis score is correlated with PCSK9 and improves ...
Jan 7, 2022 · NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study.
[67]
Statin or PCSK9 Blocking Alleviate Airway Hyperresponsiveness ...
Our findings suggest that serum lipid lowering treatments may alleviate obesity induced AHR and lung fibrosis through anti-inflammatory mechanism.
[68]
PCSK9 genetic variants and risk of vascular and non ... - PubMed
Jun 3, 2024 · The LDL-C-lowering PCSK9 genetic variants are associated with lower risk of subclinical and clinical atherosclerotic vascular disease but higher risks of ...
[69]
PCSK9 genetic variants and risk of vascular and ... - Oxford Academic
The LDL-C-lowering PCSK9 genetic variants are associated with lower risk of subclinical and clinical atherosclerotic vascular disease but higher risks of ...
[70]
PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 ...
Jan 16, 2023 · PCSK9 inhibitors are powerful lipid-lowering agents that may curtail the inflammatory response in patients with COVID-19 through reduction of ...Trial Design And Patient... · Patient Enrollment And... · Serum Il-6 And Ldl-C...<|separator|>
[71]
Association between PCSK9 inhibitor with cause-specific morality ...
Oct 28, 2024 · The use of PCSK9i was associated lower risks of all-cause, cardiovascular-related, and cancer-related mortality amongst cancer survivors.
[72]
PCSK9 Monoclonal Antibodies: New Developments and Their ... - NIH
Jul 28, 2022 · The currently available PCSK9-mAb, evolocumab and alirocumab, have been shown to not only robustly decrease LDL-C by 50–60% on top of statins ...
[73]
Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular ...
The first studies in humans in healthy volunteers 16, 17 were conducted with the fully human PCSK9 MoAb REGN727 (hereafter alirocumab) and, shortly thereafter, ...The Present And Future · Phase 2 Clinical Trials · Phase 3 And Longer-Term...
[74]
PCSK9 Inhibitors - StatPearls - NCBI Bookshelf - NIH
2 fully humanized monoclonal antibodies—alirocumab and evolocumab— have been approved by the US Food and Drug Administration (FDA) to inhibit or reduce PCSK9 ...
[75]
PCSK9 Monoclonal Antibodies: An Overview - PMC - NIH
Jun 29, 2020 · PCSK9 monoclonal antibodies have significantly reduced the low-density lipoprotein cholesterol (LDL-C) plasma level resulting in a better LDL-C ...Hypercholesterolemia · Cardiovacular Benefit · Introduction
[76]
PCSK9 inhibitors: Pharmacology, adverse effects, and use - UpToDate
Antibodies to PCSK9 bind to free PCSK9 in plasma, thereby inhibiting the binding of PCSK9 to the LDL-R, leading to higher hepatic LDL-R expression, resulting ...
[77]
Mechanism of Action (MOA) | Repatha® (evolocumab)
Normally, PCSK9 binds to the LDL receptor (LDLR) on the surface of hepatocytes, leading to the degradation of the LDLR and higher LDL-C levels.
[78]
Efficacy and Safety of Alirocumab in Reducing Lipids and ...
Mar 15, 2015 · Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels.
[79]
The PCSK9 revolution: Current status, controversies, and future ...
In short, the discovery of PCSK9 was initially identified as the third and rarest molecular cause of FH and ultimately has become the target for cholesterol ...
[80]
Efficacy and safety of PCSK9 monoclonal antibodies - NIH
The Phase I studies of evolocumab, alirocumab, and bococizumab have shown reduction in LDL-C levels in healthy volunteers and patients with familial and ...
[81]
PCSK9 Inhibition With Monoclonal Antibodies: Modern Management ...
May 16, 2016 · The PCSK9 gene was identified in the past decade as a potential therapeutic target for the management of patients with hypercholesterolemia.
[82]
Inclisiran: a new generation of lipid-lowering siRNA therapeutic - PMC
Oct 13, 2023 · Inclisiran is a novel siRNA drug that targets proprotein convertase subtilisin/kexin type 9 (PCSK9) gene expression and reduces LDL-C levels ...
[83]
Harnessing RNA Interference for Cholesterol Lowering: The Bench ...
Mar 8, 2024 · Inclisiran, a novel small interfering RNA (siRNA), lowers LDL‐C by inhibiting hepatic production of PCSK9 with twice‐yearly maintenance dosing.
[84]
Inclisiran in Cardiovascular Health: A Review of Mechanisms ... - NIH
This article summarizes inclisiran's mechanism of action, efficacy, safety, current research hotspots, clinical applications, and future development prospects
[85]
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL ...
At day 510, inclisiran reduced LDL cholesterol levels by 52.3% (95% confidence interval [CI], 48.8 to 55.7) in the ORION-10 trial and by 49.9% (95% CI, 46.6 to ...
[86]
Inclisiran for the Treatment of Heterozygous Familial ...
A twice-yearly injection of inclisiran, a small interfering RNA, was shown to inhibit hepatic synthesis of PCSK9 in adults with heterozygous familial ...
[87]
Long-term efficacy and safety of inclisiran in patients with high ...
Jan 5, 2023 · The aim of this study was to assess the effect of long-term dosing of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol.
[88]
Safety and Tolerability of Inclisiran for Treatment of ... - JACC
Dec 4, 2023 · Multiple studies, including the 4-year open-label extension (OLE) trial, ORION-3, have demonstrated that twice-yearly dosing with inclisiran ...<|control11|><|separator|>
[89]
No Safety Concerns Seen With Inclisiran in Large ORION Analysis
Dec 6, 2023 · In a pooled analysis of seven ORION studies, the mean duration of exposure to inclisiran was 2.8 years in more than 3,500 patients, with a small ...
[90]
Inclisiran administration potently and durably lowers LDL-C over an ...
Long-term data on the durability of LDL-C lowering by inclisiran were evaluated in the ORION-8 trial (NCT03814187), which analysed 3274 participants from four ...
[91]
Inclisiran: First Approval - PMC - NIH
Feb 23, 2021 · Inclisiran received its first approval in December 2020 in the EU for use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) ...
[92]
FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to ...
Dec 22, 2021 · At day 510, inclisiran reduced LDL cholesterol levels by 52.3% (95% confidence interval [CI], 48.8 to 55.7) in the ORION-10 trial and by 49.9% ...
[93]
Inhibition of PCSK9 with polypurine reverse hoogsteen hairpins
We developed a time-, cost-, and resource-efficient silencing system using Polypurine Reverse Hoogsteen (PPRH) hairpins to target PCSK9.
[94]
New Approaches for Targeting PCSK9: Small-Interfering ...
The siRNA remains bound to the RNA-induced silencing complex, therefore allowing more long-term effects than its single strand counterpart, an antisense ...
[95]
An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia
Mar 31, 2025 · The phase 2 randomized, double-blind, placebo-controlled, multicenter PURSUIT trial evaluated the efficacy and safety of AZD0780 in patients ...
[96]
Emerging oral therapeutic strategies for inhibiting PCSK9
The interaction of PCSK9 with LDL receptor elicits a dual effect (1) acting as a courier, facilitating the exit of LDL receptor from the endoplasmic reticulum, ...Emerging Oral Therapeutic... · 1. Introduction · 5. Enlicitide Decanoate...
[97]
Current and emerging PCSK9‐directed therapies to reduce LDL‐C ...
Dec 16, 2024 · This scoping review covers the development of current and emerging PCSK9-directed therapies, their efficacy, safety, and role in clinical practice.INTRODUCTION · DEVELOPMENT OF... · CARDIOVASCULAR... · GUIDELINE...
[98]
https://www.merck.com/news/merck-to-present-new-data-from-its-innovative-cardio-pulmonary-pipeline-and-portfolio-at-aha-scientific-sessions-2025/
[99]
MK-0616: The 2023 Molecule of the Year - Drug Hunter
Apr 4, 2024 · In all, MK-0616 is strongly positioned to become the first approved oral PCSK9 inhibitor. This drug discovery campaign, leading to the first ...
[100]
MSD's oral PCSK9 scores Phase III hat-trick - Clinical Trials Arena
Sep 2, 2025 · If approved, MSD's enlicitide decanoate would be the first and only oral PCSK9 on the market for hypercholesterolemia.Missing: emerging | Show results with:emerging
[101]
AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant ...
Mar 31, 2025 · AZD0780 is an investigational once-daily oral PCSK9 inhibitor for patients currently not reaching their LDL-C lowering goal despite standard-of-care-lipid ...Missing: emerging | Show results with:emerging
[102]
Efficacy and safety of AZD0780, an oral small molecule PCSK9 ...
In a phase 1 study, AZD0780 lowered LDL-C by an additional 51% in patients treated with rosuvastatin 20 mg daily. Methods: PURSUIT was a Phase 2b randomized, ...Missing: emerging | Show results with:emerging
[103]
An Oral PCSK9 Inhibitor for Lowering LDL-C? - NEJM Journal Watch
Apr 1, 2025 · In a phase 2 trial, an oral small-molecule inhibitor of PCSK9 safely lowered LDL cholesterol by up to 51% compared with placebo.
[104]
A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 ...
We report herein the discovery of NYX-PCSK9i, an orally bioavailable small-molecule inhibitor of PCSK9 with significant cholesterol-lowering activity.
[105]
Evolocumab and Clinical Outcomes in Patients with Cardiovascular ...
Mar 17, 2017 · Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol ...
[106]
What Lessons Have We Learned and What Remains to be Clarified ...
Both the FOURIER (Further cardiovascular OUtcomes Research with PCSK9 ... In both trials, there were incremental reductions in LDL-C of > 50% from baseline ...
[107]
Alirocumab and Cardiovascular Outcomes after Acute Coronary ...
Nov 7, 2018 · The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients ...<|separator|>
[108]
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events
Feb 5, 2019 · Results: With 3,064 first and 5,425 total events, 190 fewer first and 385 fewer total nonfatal cardiovascular events or deaths were observed ...
[109]
FOURIER to ODYSSEY: the end of the journey for lipid-lowering ...
This article discusses the results of the FOURIER and ODYSSEY Outcomes trials evaluating the PCSK9 inhibitors evolocumab and alirocumab in secondary ...
[110]
What Lessons Have We Learned and What Remains to be Clarified ...
Feb 5, 2020 · However, data from both trials support the notion that patients with lower levels of LDL-C still have benefit from therapy with PCSK9 inhibitors ...
[111]
Long-Term Evolocumab in Patients With Established Atherosclerotic ...
Aug 29, 2022 · During the open-label extension follow-up period, patients who were originally randomized to evolocumab had a 15% to 20% lower risk of major ...
[112]
Effect of Alirocumab on Mortality After Acute Coronary Syndromes
May 23, 2019 · A lower mortality was observed with alirocumab in the ODYSSEY OUTCOMES trial, whereas no difference in death was found with evolocumab or ...
[113]
Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With ...
Dec 9, 2017 · In contrast with a previous meta‐analysis from lipid‐lowering trials, we found no benefit in all‐cause mortality with PCSK9 inhibitor therapy.Missing: correlation | Show results with:correlation
[114]
Association of PCSK9 inhibitors with mortality: insights from a ...
Oct 4, 2024 · PCSK9 inhibitors significantly reduced all-cause mortality and medical utilization compared to statins, suggesting their important role in dyslipidaemia ...
[115]
PCSK9 Function and Cardiovascular Death: The Knot Tightens - JACC
Jun 17, 2019 · Decades-long exposure to modestly lower levels of LDL-C, mediated by functional variants in the PCSK9 gene, was associated with lower cardiovascular mortality.
[116]
Safety and Tolerability of PCSK9 Inhibitors: Current Insights - NIH
Dec 11, 2020 · Mounting scientific and clinical evidence supports that PCSK9 inhibitors offer an excellent safety and tolerability profile with a low incidence of adverse ...
[117]
Real-world safety of PCSK9 inhibitors: A pharmacovigilance study ...
Nov 23, 2022 · Compared with various statins and ezetimibe, PCSK9 inhibitors have shown a favorable safety profile in muscle-related events, cognitive ...Abstract · Materials and methods · Results · Discussion
[118]
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors ...
Jul 15, 2021 · Pooled results of our meta-analysis and meta-regression show that exposure to PCSK9 inhibitors is not associated with an increased risk of neurocognitive ...
[119]
Adverse event profiles of PCSK9 inhibitors alirocumab and ...
Jul 12, 2022 · A meta-analysis of 35 RCTs has indicated that PCSK9 inhibitors can be associated with elevated creatine kinase. Our findings also revealed ...INTRODUCTION · PATIENTS AND METHODS · RESULTS · DISCUSSION
[120]
Restoring mortality data in the FOURIER cardiovascular outcomes ...
Our readjudication of mortality outcomes showed that deaths of cardiac origin were numerically higher in the evolocumab group (113) than with placebo (88), ...
[121]
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 ...
Extended treatment with evolocumab in the group initially randomized to evolocumab was safe, well-tolerated, and associated with fewer cardiovascular events and ...
[122]
Genetic Assessment of Potential Long-Term On-Target Side Effects ...
Jan 15, 2019 · Our findings support previous genetic analyses suggesting that long-term use of PCSK9 inhibitors, like statins, may be associated with increased risk of T2DM.<|separator|>
[123]
An Updated Meta-Analysis for Safety Evaluation of Alirocumab ... - NIH
The overall incidence of long-term adverse events in PCSK9 inhibitor therapy is rather high at 75.1%, but it should be evaluated through (possibly indirect) ...
[124]
Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy
A growing body of scientific and clinical evidence shows that PCSK9-targeted therapy offers an excellent safety and tolerability profile with a low incidence ...
[125]
PCSK9 Inhibition to Reduce Cardiovascular Risk
May 12, 2017 · PCSK9 inhibitors also reduce cardiovascular events; however, as shown in the Figure, the reductions in FOURIER and SPIRE fall well below what ...Missing: controversies | Show results with:controversies
[126]
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk ...
Mar 17, 2017 · In conclusion, the SPIRE-1 and SPIRE-2 trials of PCSK9 inhibition with bococizumab were terminated early by the sponsor owing to the ...Missing: discrepancies | Show results with:discrepancies
[127]
SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab
Mar 17, 2017 · Data from the SPIRE clinical trial program show the benefit of using this class of drug as an adjunct to statin therapy in patients with high LDL cholesterol.Missing: discrepancies | Show results with:discrepancies
[128]
Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality ...
May 28, 2019 · Although alirocumab reduced the risk of all-cause mortality by 15% in ODYSSEY Outcomes, there was no effect on the risk of death in FOURIER with ...<|separator|>
[129]
A Meta-analysis of Randomized Controlled Trials
Jan 19, 2024 · According to the study, PCSK9 inhibitors did not improve both all-cause and cardiovascular-specific mortality while significantly reducing MI ...
[130]
Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group ...
Jan 5, 2023 · They identified 11 more deaths from MI in the evolocumab-treated patients and three fewer deaths from MI in the placebo group than reported in ...
[131]
Recount of FOURIER Data Finds Higher Mortality With Evolocumab
Jan 6, 2023 · Readjudication of mortality data from the FOURIER trial suggests a higher risk for cardiovascular death with evolocumab (Repatha) among patients with ...
[132]
Critical Appraisal of the 2018 ACC Scientific Sessions Late-Breaking ...
May 9, 2018 · Inconsistencies are that ODYSSEY shows apparent reductions in both unstable angina and in all-cause death, whereas FOURIER does not. This ...
[133]
Adverse Events Associated With PCSK9 Inhibitors: A Real‐World ...
Jul 27, 2018 · In conclusion, in a real-world setting, PCSK9 inhibitors are well tolerated. Most common AEs are influenza-like illness, nasopharyngitis, ...
[134]
Low LDL, High Reassurance? Evolocumab's Long-Term Cognitive ...
Dec 24, 2024 · Early clinical trials demonstrated that PCSK9 inhibitors lowered low-density lipoprotein cholesterol (LDL-C) levels by approximately 60%.
[135]
PCSK9 Inhibitors and Infection-Related Adverse Events - NIH
Jul 2, 2024 · ... PCSK9 inhibitors and infection. A recent systematic review and meta-analysis study demonstrated that there is no detrimental association ...
[136]
Evaluating the role of PCSK9 inhibitors in reducing cardiovascular ...
Jan 30, 2025 · PCSK9 inhibitors are effective and safe alternatives for LDL-C reduction and cardiovascular risk mitigation in patients with statin intolerance.Missing: inconsistencies | Show results with:inconsistencies
[137]
PCSK9 inhibition: from effectiveness to cost-effectiveness - Frontiers
PCSK9 inhibitors represent a revolutionary solution for lowering LDL cholesterol, but their cost-effectiveness remains controversial.Abstract · Introduction · Results · Discussion
[138]
Medical and Financial Consequences of Using PCSK9 Inhibitors for ...
Sep 25, 2025 · The mean annual medication costs for patients treated with PCSK9 inhibitors were USD 8509.09 versus USD 3801.32, resulting in a mean difference ...
[139]
Impact of manufacturer-initiated list price reduction on patient out-of ...
Sep 25, 2024 · Because of concerns of cost-effectiveness and low utilization, in 2018, manufacturers initiated a 60% price reduction for PCSK9 inhibitors, ...
[140]
PCSK9 Inhibitors: Economics and Policy - JACC
Statin therapy was consistently more cost-effective when used as secondary prevention, with ICERs <$15,000 per life-year added. This insight—that the same ...
[141]
Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin ...
Nov 9, 2024 · Recent studies demonstrate that inclisiran is well tolerated over the long term, showing a diminished risk of myopathy and hepatotoxicity ...
[142]
Abstract 60: Cost-Effectiveness of Intensive Lipid-Lowering in Young ...
May 16, 2024 · To be highly cost-effective for young adults with LDL-C ≥190 mg/dL, PCSK9-I prices would need to be reduced by 61%. Conclusion: With generic ...
[143]
Research Confirms Prior Authorization Burden for Heart Patients
82-97 percent of health plans require prior authorization for PCSK9 inhibitors. · Many plans ask doctors to submit patients' actual medical records · Many plans ...
[144]
Life saving medicine still being denied - Family Heart Foundation
Feb 20, 2024 · Family Heart Foundation research shows insurance coverage for PCSK9 inhibitors remains a barrier leaving patients at risk.
[145]
Insurers reject PCSK9 inhibitors at a higher rate vs. other ... - Healio
Feb 29, 2024 · “Prior authorization barriers and high out-of-pocket costs for therapies such as the PCSK9 inhibitors can serve as significant disincentives ...
[146]
Trends in Patient Access to and Utilization of Prescribed PCSK9 ...
Feb 16, 2024 · PCSK9 inhibitor access barriers-issues and recommendations: improving the access process for patients, clinicians and payers. Clin Cardiol ...
[147]
PCSK9 inhibitor access barriers—issues and recommendations - NIH
Given the high denial rate for the PCSK9 mab, such a requirement clearly represents an untenable financial barrier for physicians.
[148]
The Role of Specialty Pharmacists in Overcoming Barriers ...
Aug 4, 2023 · Insurance companies will typically approve access to PCSK9 inhibitors if a patient is already on a maximally tolerated statin or has not ...
[149]
Merck's Investigational Oral PCSK9 Inhibitor Enlicitide Decanoate ...
Sep 2, 2025 · Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C compared ...
[150]
Merck's Oral PCSK9 Inhibitor Demonstrates Efficacy in ...
Sep 3, 2025 · “Enlicitide, designed to deliver antibody-like efficacy, is the first oral macrocyclic peptide PCSK9 inhibitor with clinically meaningful and ...
[151]
Verve Therapeutics Announces Pipeline Progress and Reports First ...
May 14, 2025 · Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results · PCSK9 Program · ANGPTL3 Program · LPA Program<|separator|>
[152]
A potent epigenetic editor targeting human PCSK9 for durable ...
Feb 10, 2025 · In this study, we designed an epigenetic editor to target human PCSK9 and thereby induce DNA methylation at this locus.
[153]
https://www.sciencedaily.com/releases/2025/10/251022023122.htm
[154]
Discovery and preclinical development of a potent epigenic editor ...
Apr 22, 2025 · At present, multiple gene editing approaches are being applied to silence PCSK9 both in preclinical models and in early clinical development.
[155]
LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ...
Oct 2, 2025 · Repatha is the most extensively studied PCSK9 inhibitor, with clinical and real-world evidence across diverse populations and CV risk profiles.6.Missing: ongoing | Show results with:ongoing
[156]
Targeting PCSK9 beyond the liver: evidence from experimental and ...
Mar 30, 2025 · Introduction: PCSK9 has been widely studied as a target for lipid-lowering as its inhibition increases LDLR recycling on the surface of ...Missing: novel | Show results with:novel
[157]
The discovery of PCSK9 as a pivotal point in the prevention of ...
The discovery of PCSK9 and subsequent development of PCSK9 inhibitors (PCSK9i) have helped usher a new era of non-statin lipid-lowering therapy for ...State-Of-The-Art Review · 2. Pcsk9 Structure And... · 3. Clinical Trials Of Pcsk9...Missing: timeline | Show results with:timeline
[158]
The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer's ...
Dec 20, 2024 · PCSK9 appeared to be directly involved in some of the principal processes responsible for AD development, such as inflammation, oxidative stress, and Aβ ...
[159]
Elevated circulating PCSK9 level is associated with 28-day mortality ...
Oct 31, 2023 · This study demonstrated that PCSK9 levels at or above 370 ng/ml significantly increase the risk of 28-day mortality in sepsis, providing ...
[160]
PCSK9: A Potential Therapeutic Target for Sepsis - PMC - NIH
Oct 14, 2020 · Plasma PCSK9 levels are greatly increased in sepsis. During sepsis, PCSK9 levels are highly correlated with the development of subsequent ...
[161]
The association between PCSK9 inhibitor use and sepsis - PubMed
Mar 13, 2023 · Conclusion: There was neither a beneficial nor a harmful association between PCSK9 inhibitors and risk of sepsis or severe infections. These ...
[162]
PCSK9 Inhibitors and Infection-Related Adverse Events
Jul 2, 2024 · This analysis demonstrated that PCSK9 inhibitor use was not linked to severe infection-related AEs, including sepsis, when compared with placebo ...
[163]
A Genetic Approach to the Association Between PCSK9 and Sepsis
Sep 11, 2019 · These findings suggest that PCSK9 genetic variations are not significantly associated with the risk of sepsis in patients hospitalized with infection.
[164]
PCSK9 ablation attenuates Aβ pathology, neuroinflammation and ...
PCSK9 loss improves cognitive performance in 5XFAD mice, a severe mouse model of AD. PCSK9 ablation reduces Aβ plaque deposition and microglia activation.
[165]
Investigating PCSK9 inhibition as potential strategy in Alzheimer's ...
Conclusions: Our in vitro results show the protective role of PCSK9 pharmacological inhibition with small molecules on Aβ-induced neurotoxicity and ...
[166]
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to ...
Jul 30, 2025 · This study strongly supports the idea that peripheral PCSK9 inhibition could be a novel and easily implementable tool to increase cerebral Aβ ...<|separator|>
[167]
Mendelian Randomization Study of PCSK9 and HMG-CoA ... - JACC
Aug 8, 2022 · Neither PCSK9 nor HMGCR inhibition impacted biomarkers of Alzheimer's disease progression or Lewy body dementia risk. Consistency of findings ...
[168]
Neurocognitive effects associated with proprotein convertase ...
PCSK9 inhibitors and genetic variants leading to sustained low LDL-C concentrations may also promote the cardiovascular risk factors for Alzheimer's disease and ...
[169]
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
Nov 11, 2020 · Here we show that inhibiting PCSK9—a key protein in the regulation of cholesterol metabolism—can boost the response of tumours to immune ...
[170]
Cholesterol Drugs to Improve Cancer Immunotherapy - NCI
Dec 10, 2020 · The researchers found that PCSK9 affects how much MHC I sits on the surface of cancer cells. Deleting PCSK9 or blocking its activity with ...
[171]
Targeting PCSK9 reduces cancer cell stemness and enhances ...
May 18, 2023 · Here, we found that the expression of PCSK9 was upregulated in HNSCC tissues, and higher PCSK9 expression indicated poorer prognosis in HNSCC patients.
[172]
PCSK9 promotes the progression and metastasis of colon cancer ...
Oct 14, 2022 · PCSK9 played an important role in the progression and metastasis of colon cancer by regulation of tumor cell EMT and PI3K/AKT signaling and in the phenotypic ...
[173]
Inhibition of PCSK9: A Promising Enhancer for Anti-PD-1/PD-L1 ...
Sep 25, 2024 · Thus, the inhibition of PCSK9 can suppress tumor development to a certain degree by lowering serum cholesterol levels. Targeting PCSK9 is not ...